Allogeneic HSCT is the only curative therapy for hematological complications of GATA2 deficiency and has been shown to eradicate clonal malignancy, restore normal hematopoiesis, clear underlying infections, and improve pulmonary function. The gene discussed is GATA2; the disease is infection.